- Home
- ROIV vs LI Comparison
ROIV vs LI Comparison
Compare ROIV & LI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | LI |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United Kingdom | China |
| Employees | N/A | 30728 |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 19.1B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ROIV | LI |
|---|---|---|
| Price | $29.34 | $20.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 10 |
| Target Price | ★ $28.94 | $19.66 |
| AVG Volume (30 Days) | ★ 4.4M | 2.4M |
| Earning Date | 05-28-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,053,000.00 | N/A |
| Revenue This Year | N/A | $18.98 |
| Revenue Next Year | $744.61 | $22.72 |
| P/E Ratio | ★ N/A | $29.50 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.58 | $15.71 |
| 52 Week High | $30.33 | $32.03 |
Technical Indicators
Market Signals| Indicator | ROIV | LI |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 69.57 |
| Support Level | $27.00 | $16.30 |
| Resistance Level | $30.26 | $20.57 |
| Average True Range (ATR) | 0.87 | 0.45 |
| MACD | 0.09 | 0.16 |
| Stochastic Oscillator | 85.95 | 97.39 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About LI Li Auto Inc.
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.